File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Future prevention and treatment of chronic hepatitis B infection
  • Basic View
  • Metadata View
  • XML View
TitleFuture prevention and treatment of chronic hepatitis B infection
 
AuthorsSeto, WK1
Fung, J1
Yuen, MF1 1
Lai, CL1 1
 
Keywordsbesifovir
FG-3019
HELIPSAV
interferon-λ
REP 9AC
vaccination
 
Issue Date2012
 
PublisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.jcge.com
 
CitationJournal of Clinical Gastroenterology, 2012, v. 46 n. 9, p. 725-734 [How to Cite?]
DOI: http://dx.doi.org/10.1097/MCG.0b013e3182610191
 
AbstractVaccination for hepatitis B virus (HBV) infection and treatment for chronic hepatitis B, while effective for primary prevention and control of the disease, still have their limitations. Global coverage of HBV immunization needs improvement. Several patient populations are noted to have suboptimal seroprotective rates after HBV vaccination. There are currently several potential new vaccines undergoing animal and human studies, most notably vaccines containing immunostimulatory DNA sequences. Long-term nucleoside analogue therapy is necessary in achieving permanent virologic suppression. Potential new treatments explore new mechanisms of action, including the inhibition of hepatitis B surface antigen release, targeting antifibrotic mechanism, and immunomodulation through novel interferons and therapeutic vaccines. The clinical application of potential new vaccines and therapies would enhance the prevention of HBV infection and treatment of chronic hepatitis B. © 2012 by Lippincott Williams & Wilkins.
 
ISSN0192-0790
2012 Impact Factor: 3.203
2012 SCImago Journal Rankings: 1.188
 
DOIhttp://dx.doi.org/10.1097/MCG.0b013e3182610191
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorSeto, WK
 
dc.contributor.authorFung, J
 
dc.contributor.authorYuen, MF
 
dc.contributor.authorLai, CL
 
dc.date.accessioned2012-09-20T07:58:12Z
 
dc.date.available2012-09-20T07:58:12Z
 
dc.date.issued2012
 
dc.description.abstractVaccination for hepatitis B virus (HBV) infection and treatment for chronic hepatitis B, while effective for primary prevention and control of the disease, still have their limitations. Global coverage of HBV immunization needs improvement. Several patient populations are noted to have suboptimal seroprotective rates after HBV vaccination. There are currently several potential new vaccines undergoing animal and human studies, most notably vaccines containing immunostimulatory DNA sequences. Long-term nucleoside analogue therapy is necessary in achieving permanent virologic suppression. Potential new treatments explore new mechanisms of action, including the inhibition of hepatitis B surface antigen release, targeting antifibrotic mechanism, and immunomodulation through novel interferons and therapeutic vaccines. The clinical application of potential new vaccines and therapies would enhance the prevention of HBV infection and treatment of chronic hepatitis B. © 2012 by Lippincott Williams & Wilkins.
 
dc.description.naturepostprint
 
dc.identifier.citationJournal of Clinical Gastroenterology, 2012, v. 46 n. 9, p. 725-734 [How to Cite?]
DOI: http://dx.doi.org/10.1097/MCG.0b013e3182610191
 
dc.identifier.doihttp://dx.doi.org/10.1097/MCG.0b013e3182610191
 
dc.identifier.epage734
 
dc.identifier.hkuros210584
 
dc.identifier.issn0192-0790
2012 Impact Factor: 3.203
2012 SCImago Journal Rankings: 1.188
 
dc.identifier.issue9
 
dc.identifier.pmid22914347
 
dc.identifier.scopuseid_2-s2.0-84866240582
 
dc.identifier.spage725
 
dc.identifier.urihttp://hdl.handle.net/10722/164364
 
dc.identifier.volume46
 
dc.languageeng
 
dc.publisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.jcge.com
 
dc.publisher.placeUnited States
 
dc.relation.ispartofJournal of Clinical Gastroenterology
 
dc.relation.referencesReferences in Scopus
 
dc.rightsThis is a non-final version of an article published in final form in Journal of Clinical Gastroenterology, 2012, v. 46 n. 9, p. 725-734
 
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License
 
dc.subjectbesifovir
 
dc.subjectFG-3019
 
dc.subjectHELIPSAV
 
dc.subjectinterferon-λ
 
dc.subjectREP 9AC
 
dc.subjectvaccination
 
dc.titleFuture prevention and treatment of chronic hepatitis B infection
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Seto, WK</contributor.author>
<contributor.author>Fung, J</contributor.author>
<contributor.author>Yuen, MF</contributor.author>
<contributor.author>Lai, CL</contributor.author>
<date.accessioned>2012-09-20T07:58:12Z</date.accessioned>
<date.available>2012-09-20T07:58:12Z</date.available>
<date.issued>2012</date.issued>
<identifier.citation>Journal of Clinical Gastroenterology, 2012, v. 46 n. 9, p. 725-734</identifier.citation>
<identifier.issn>0192-0790</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/164364</identifier.uri>
<description.abstract>Vaccination for hepatitis B virus (HBV) infection and treatment for chronic hepatitis B, while effective for primary prevention and control of the disease, still have their limitations. Global coverage of HBV immunization needs improvement. Several patient populations are noted to have suboptimal seroprotective rates after HBV vaccination. There are currently several potential new vaccines undergoing animal and human studies, most notably vaccines containing immunostimulatory DNA sequences. Long-term nucleoside analogue therapy is necessary in achieving permanent virologic suppression. Potential new treatments explore new mechanisms of action, including the inhibition of hepatitis B surface antigen release, targeting antifibrotic mechanism, and immunomodulation through novel interferons and therapeutic vaccines. The clinical application of potential new vaccines and therapies would enhance the prevention of HBV infection and treatment of chronic hepatitis B. &#169; 2012 by Lippincott Williams &amp; Wilkins.</description.abstract>
<language>eng</language>
<publisher>Lippincott Williams &amp; Wilkins. The Journal&apos;s web site is located at http://www.jcge.com</publisher>
<relation.ispartof>Journal of Clinical Gastroenterology</relation.ispartof>
<rights>This is a non-final version of an article published in final form in Journal of Clinical Gastroenterology, 2012, v. 46 n. 9, p. 725-734</rights>
<rights>Creative Commons: Attribution 3.0 Hong Kong License</rights>
<subject>besifovir</subject>
<subject>FG-3019</subject>
<subject>HELIPSAV</subject>
<subject>interferon-&#955;</subject>
<subject>REP 9AC</subject>
<subject>vaccination</subject>
<title>Future prevention and treatment of chronic hepatitis B infection</title>
<type>Article</type>
<description.nature>postprint</description.nature>
<identifier.doi>10.1097/MCG.0b013e3182610191</identifier.doi>
<identifier.pmid>22914347</identifier.pmid>
<identifier.scopus>eid_2-s2.0-84866240582</identifier.scopus>
<identifier.hkuros>210584</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-84866240582&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>46</identifier.volume>
<identifier.issue>9</identifier.issue>
<identifier.spage>725</identifier.spage>
<identifier.epage>734</identifier.epage>
<publisher.place>United States</publisher.place>
<bitstream.url>http://hub.hku.hk/bitstream/10722/164364/1/Content.pdf</bitstream.url>
</item>
Author Affiliations
  1. The University of Hong Kong